VanEck Biotech ETF
BBH
112 hedge funds and large institutions have $130M invested in VanEck Biotech ETF in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 32 reducing their positions, and 10 closing their positions.
105% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $874K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
0% more funds holding
Funds holding: 112 → 112 (0)
2.4% less ownership
Funds ownership: 35.44% → 33.03% (-2.4%)
22% less capital inflows, than outflows
Capital inflows: $7.32M | Capital outflows: $9.4M
44% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 32
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.25M |
| 2 |
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$1.02M |
| 3 |
Equitable Holdings
New York
|
+$985K |
| 4 |
Corient Private Wealth
Miami,
Florida
|
+$788K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$746K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ascent Advisors
Mankato,
Minnesota
|
-$2.68M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.15M |
| 3 |
Atlas Capital Advisors
Jackson,
Wyoming
|
-$1.02M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$762K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$741K |
BBH Hedge Fund Activity: Q2 2026 in Review
112 of the 8,384 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2026, worth a combined $130M — up 5.9% from $123M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BBH positions and 10 closed out — a net gain of 2 holders — while 18 added to existing stakes and 32 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.25M. The largest seller was Ascent Advisors, exiting entirely with an estimated $2.68M sold.
- 112 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $130M of VanEck Biotech ETF stock for Q2 2026, up 5.9% quarter-over-quarter.
- 12 funds opened new VanEck Biotech ETF positions in Q2 2026 and 10 closed out, a net change of +2 holders.
- The largest VanEck Biotech ETF buyer in Q2 2026 was Morgan Stanley, an estimated $1.25M added.
- The largest VanEck Biotech ETF seller in Q2 2026 was Ascent Advisors, an estimated $2.68M sold.
Based on aggregated 13F filings for Q2 2026.